title: Anesthesia specific differences in a cardio-pulmonary resuscitation rat model; halothane versus sevoflurane.
abstract: Our asphyxia cardiac arrest (ACA) rat model is well established. The original model was designed in the 1990th using halothane and nitrous oxide for pre-insult anesthesia. Because of its hepato-toxicity and its potential to induce severe liver failures, halothane is no longer used in clinical anesthesia for several years. In order to minimize the health risk for our laboratory staff as well as to keep the experimental settings of our model on a clinically oriented basis we decided to replace halothane by sevoflurane. In this study we intended to determine if the change of the narcotic gas regiment causes changes in the neurological damage and how far our model had to be adjusted.
  
  
  
  Adult rats were subjected to 5min of ACA followed by resuscitation. There were four treatment groups: ACA - halothane, ACA - sevoflurane and with halothane or sevoflurane sham operated animals. Vital and blood parameters were monitored during the 45min post-resuscitation intensive care phase. After a survival time of 7 days histological evaluation of the hippocampus was performed.
  
  
  
  We observed that resuscitated rats anesthetized prior by sevoflurane (i) have had a lower heart rate and a higher MAP compared to halothane anesthetized animals; (ii) The neurological damaged were significantly reduced in the hippocampal CA1 region in sevoflurane treated rats.
  
  
  
  Using sevoflurane instead of halothane for anesthesia requires some physiological and experimental changes. However the model keeps its validity. Sevoflurane caused less pronounced neurodegeneration in the CA1 region of the hippocampus. This had to be considered in further resuscitation-studies containing sevoflurane as anesthetic. Institutional protocol number for animal studies: 42502-2-2-947 Uni MD.
authors.affiliation: Department of Anaesthesiology, University of Magdeburg, Leipziger Strasse 44, Magdeburg, Germany. Electronic address: torben.esser@med.ovgu.de.
authors.forename: Torben
authors.initials: T
authors.lastname: Esser
authors.affiliation: Institute of Biochemistry and Cell Biology, University of Magdeburg, Leipziger Strasse 44, Magdeburg, Germany.
authors.forename: Gerburg
authors.initials: G
authors.lastname: Keilhoff
authors.affiliation: Department of Anaesthesiology, University of Magdeburg, Leipziger Strasse 44, Magdeburg, Germany.
authors.forename: Uwe
authors.initials: U
authors.lastname: Ebmeyer
mesh_terms: D018685:Anesthetics, Inhalation / Q000008:administration & dosage*; D000818:Animals; D001237:Asphyxia / Q000473:pathology / Q000628:therapy; D056547:CA1 Region, Hippocampal / Q000187:drug effects / Q000473:pathology; D016887:Cardiopulmonary Resuscitation; D004195:Disease Models, Animal; D006221:Halothane / Q000008:administration & dosage*; D006323:Heart Arrest / Q000473:pathology / Q000628:therapy; D006339:Heart Rate / Q000187:drug effects; D007150:Immunohistochemistry; D008297:Male; D008738:Methyl Ethers / Q000008:administration & dosage*; D019636:Neurodegenerative Diseases / Q000209:etiology / Q000473:pathology; D017208:Rats, Wistar; D000077149:Sevoflurane
chemical_list: D018685:Anesthetics, Inhalation; D008738:Methyl Ethers; D000077149:Sevoflurane; D006221:Halothane
keywords: Cardiac arrest; Halothane; Hippocampus; Neurodegeneration; Resuscitation; Sevoflurane